Archives
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-11
- 2018-10
- 2018-07
-
br Implementation of sacubitril valsartan into
2024-05-25

Implementation of sacubitril/valsartan into clinical practice Following on from the results of PARADIGM-HF, sacubitril/valsartan was given regulatory approval for use in patients who conform to the main inclusion criteria of the trial; NYHA functional class II–IV, reduced left ventricular ejectio
-
CD 2665 Recent results suggest that TARPs are
2024-05-25

Recent results suggest that TARPs are not the only auxiliary AMPAR subunits. Using a proteomic strategy (affinity purification of native AMPAR complexes followed by mass-spectrometric analysis), cornichon-related proteins (CNIHs) have been recently identified as components of the AMPAR protein micro
-
br Development of lorlatinib from crizotinib to a clinical
2024-05-25

Development of lorlatinib from crizotinib (1) to a clinical candidate (6) Xalkori (1, PF-02341066, crizotinib), was the first-in-class ALK inhibitor approved by the Unites States Food and Drug Administration (FDA) in 2011 as a first-line treatment for ALK+- NSCLC patients. This section describes
-
On the other hand there was
2024-05-25

On the other hand, there was no difference in effectiveness performing ALK by FISH with regard to the sample site. When it was extracted from the primary tumor, we obtained 27.4% of not-evaluable specimens. Similar percentages were found for node (26.7%) and Betaine mg (31.3%) samples (p = 0.903).
-
The aldehyde reductase AKR A
2024-05-25

The aldehyde reductase (AKR1A1) and aldose reductase (AKR1B1) belong to aldo-ketoreductase (AKR) superfamily catalyzing the reduction of corresponding aldehydes and ketones involved. Both the closely related enzymes AKR1A1 and AKR1B1 have 65% structural similarity and differ only at the active site.
-
It was recently shown that AHR and HIF cooperate to
2024-05-25

It was recently shown that AHR and HIF-1α cooperate to support the metabolism of Tr1 Quercetin [6]. Interestingly, AHR and HIF-1α act sequentially to orchestrate the metabolic remodeling of lymphocytes. While HIF-1α regulates the early metabolic reprogramming of Tr1 cells, AHR takes over at later t
-
br Role of OCT in
2024-05-25

Role of OCT3 in histamine clearance Histamine is a powerful neuromodulator, as well as a regulator of immune processes and vascular tone in the central nervous system (Gross, 1981; Haas et al., 2008; Jutel et al., 2006). In contrast to 5-HT and the catecholamines, a high-affinity transporter for
-
Digoxigenin-11-dUTP receptor Our co IP data show
2024-05-25

Our co-IP data show that 5HT1A or 5HT2A receptors do not heterodimerize with mGluR1α receptors. Given that both 5-HT and mGlu receptors are GPCRs and produce anxiolytic effects, a degree of cooperativity via a functional cross-talk may still exist between these receptors [11]. In addition to the fun
-
br ACK signaling partners ACK
2024-05-24

ACK1 signaling partners ACK1 interacts with and tyrosine phosphorylates many cellular proteins regulating critical cellular processes [11]. While ACK1 shares common intracellular effectors such as AKT with other signaling pathways, it imparts specificity to signaling by phosphorylating effectors
-
br Discussion Myopathic EMG changes are frequently detected
2024-05-24

Discussion Myopathic EMG changes are frequently detected in patients with MuSK MG, unlike in AChR MG patients [10]. However, these EMG changes are not always accompanied by myopathic histopathological findings. It has been shown that mitochondrial abnormalities seem to be more prominent in MuSK M
-
In an effort to determine if one ARI was more
2024-05-24

In an effort to determine if one 5ARI was more effective than the other, the Enlarged Prostate International Comparator Study (EPICS) [17] compared treatment with finasteride and dutasteride in 1630 men over the age of 50 and concluded that after one year of treatment, both groups had statistically
-
br Introduction Stroke is a devastating condition
2024-05-24

Introduction Stroke is a devastating condition that causes cognitive and motor dysfunction, neurodegenerative diseases and even acute death, and is a leading cause of mortality and morbidity worldwide (Chen et al., 2014a, Wang et al., 2016). Thus, exploration or identification of novel therapeuti
-
Recent studies have indicated that V ATPase activity
2024-05-24

Recent studies have indicated that V-ATPase activity negatively regulates vacuolar fusion in vivo[17]. Since we have demonstrated that the pah1Δ glucocorticoid receptors have a more acidic vacuolar pH than the WT cells, and the genes involved in the pump activity are upregulated compared to WT, the
-
Placental cells also express P
2024-05-24

Placental cells also express P450 aromatase (CYP19A1, encoded by CYP19A1). In the placenta, this enzyme requires an external source of androgens, provided by the adrenal gland of the fetus, to form estrogen. The fetal adrenal gland produces dehydroepiandrosterone (DHEA) [9] and, in the placenta, it
-
br Acknowledgements This study was funded the Irish Departme
2024-05-24

Acknowledgements This study was funded the Irish Department of Agriculture, Food and the Marine through the research program FIRM/RSF/CoFoRD (Reference: 13 F 462). The authors declare no conflict of interest. Introduction Radiotherapy (RT) is one of the major treatment methods among patients
16493 records 149/1100 page Previous Next First page 上5页 146147148149150 下5页 Last page